PLL Therapeutics focuses on restoring gut permeability. Its initial indication is Amyotrophic Lateral Sclerosis (ALS), a fatal motor neuron disease. The company’s therapy, PLL001, consists of several ...

I pray that she carries the love that she felt tonight every day that she has," said friend Rita Monteiro, who organized the ...

The EMA recommended that NUZ-001, formerly monepantel, be granted orphan medicinal product designation to treat ALS in Europe ...

Ractigen Therapeutics, a clinical-stage pharmaceutical company dedicated to developing innovative therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug ...

The St. Peter’s Hospital ALS Regional Center gives specialized services and resources to people with Amyotrophic Lateral ...

Lee Wilson discovered she has a "100%" chance of developing ALS, after losing her father and grandmother to the disease ...

A Phase 2 trial testing oral ROCK inhibitor Bravyl in people with ALS is now fully enrolled at its highest dosing group.

ALS is a progressive neurodegenerative disease that affects nerve cells in the brain and the spinal cord, ultimately leading to muscle weakness and paralysis. ALS is an orphan disease, but its ...

In a landmark continuing collaboration, Answer ALS and Cedars-Sinai have announced the completed availability of the largest amyotrophic lateral sclerosis (ALS) patient-based induced pluripotent stem ...

Grammy winner John Driskell Hopkins, known as "Hop" from the Zac Brown Band, is turning his personal battle with amyotrophic ...

Presented full dataset from first-in-human Phase 1a clinical trial demonstrating PMN310 was generally well-tolerated with monthly dosing and that ...